SLN vs VNDA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VNDA Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vanda Pharmaceuticals Inc. (VNDA) driven by superior Valuation, Growth & Margin while SLN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SLN trades at N/M Forward P/E with -10475.6% operating margin (+197.2% YoY revenue) versus VNDA at 103.1x Forward P/E and -77.6% operating margin (+24.1% YoY). In options structure, SLN sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against VNDA sits in BREAKDOWN (75th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SLN | VNDA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.2B | $238.9M | Larger Scale | SLN |
| Trailing P/E Ratio Valuation | N/M | 103.1x | Lower Multiple | VNDA |
| Forward P/E Ratio Valuation | N/M | 103.1x | Lower Multiple | VNDA |
| Revenue Growth (YoY) Growth | +197.2% | +24.1% | Higher Growth | SLN |
| Operating Margin (TTM) Profitability | -10475.6% | -77.6% | Higher Margin | VNDA |
| Net Profit Margin Profitability | 0.0% | -119.9% | Higher Margin | SLN |
| Return on Equity (ROE) Capital Efficiency | -90.4% | -82.5% | Higher ROE | VNDA |
| 52-Week Range Position Momentum | 100% ($4โ$20) | 4% ($4โ$10) | Stronger Trend | SLN |
| Beta / 30D Volatility Risk Regime | 1.92ฮฒ ยท 4% Vol | 1.25ฮฒ ยท 61% Vol | Lower Realized Risk | SLN |
| Unified Institutional Score Composite Signal | 46.9 / 100 (HOLD) | 49.0 / 100 (HOLD) | Higher Composite | VNDA |